Please select the option that best describes you:
Would you consider first line FOLFOXIRI and cetuximab or panitumumab for physically fit patients with metastatic RAS/BRAF WT colon cancer?
Instead of FOLFOXIRI and bevacizumab as per TRIBE trial
Answer from: Medical Oncologist at Community Practice
The VOLFI study is a phase II trial comparing modified FOLFOXIRI plus panitumumab to mFOLFOXIRI. The study showed an improved overall response rate (ORR) of 87.3% v 60.6% (odds ratio, 4.469; 95% CI, 1.61 to 12.38; P = .004). The secondary resection rate was also improved with the addition of panitum...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I do use FOLFOXIRI plus PANI when I desperately need tumor shrinkage to take the patient for a resection. However, I make sure the tumor is HER2’ non-amplified apart from being left-sided and RAS/RAF wild type. I also give 5FU 2,400 mg per meter square dose because if you look at the dose dens...
Answer from: Medical Oncologist at Academic Institution
The decision would depend on the sidedness of the primary tumor. Based on the PARADIGM study result (combined with phase III CALGB/SWOG 80405 trial, FIRE-3 study, and meta-analysis result, etc), for left sided primary KRAS/NRAS/BRAF WT metastatic colorectal cancer, it will be very reasonable to cons...
Answer from: Medical Oncologist at Academic Institution
No, at this point I am only utilizing FOLFOXIRI with Bevacizumab in triplet-eligible patients on the basis of the randomized Phase III TRIPLETE trial presented at ASCO Annual Meeting 2022. That study randomized newly diagnosed RAS/BRAF wild type patients to receive either 1L FOLFOXIRI/Panitumumab or...